Zevra Therapeutics Inc. (ZVRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $540.30M
Last updated: Nov 17, 2026 at 11:06 AM ET
Zevra Therapeutics Inc. (ZVRA) Stock Forecast
Analysts expect Zevra Therapeutics (ZVRA) to earn $1.12 per share in the fiscal year ending Dec 31, 2026, on revenue of $152.83M. Of 9 analysts, 9 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 1.78, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 22.2% |
| Buy | 7 | 77.8% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 12.5% and revenue estimates rise 17.8%.
- Fiscal year ending Dec 31, 2026
- $1.12
- EPS consensus, revenue $152.83M
- Fiscal year ending Dec 31, 2027
- $0.98
- EPS consensus, revenue $180.00M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.12 | $1.12 to $1.12 | 1 | $152.83M | $150.00M to $156.90M | 8 |
| Dec 31, 2027 | $0.98 | $0.75 to $1.30 | 4 | $180.00M | $157.10M to $201.96M | 9 |
Quarterly Estimates
The EPS consensus rises from $0.19 for the quarter ending Dec 31, 2026 to $0.27 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.19 | $0.13 to $0.25 | 11 | $41.02M | $36.55M to $45.42M | 11 |
| Mar 31, 2027 | $0.27 | $0.15 to $0.47 | 3 | $41.33M | $33.90M to $51.97M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 5.7% from $1.06.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.12 | $1.14 | $1.14 | $1.14 | $1.06 | +5.7% |
| Fiscal year ending Dec 31, 2027 | $0.98 | $1.05 | $1.05 | $1.05 | $1.10 | -11.0% |
| Quarter ending Mar 31, 2027 | $0.27 | $0.30 | $0.30 | $0.30 | $0.24 | +12.5% |
Frequently Asked Questions About ZVRA
What is the ZVRA stock forecast?
Consensus analyst estimates put Zevra Therapeutics's EPS at $1.12 for the fiscal year ending Dec 31, 2026, on revenue of $152.83M. The consensus rating from 9 analysts is Buy.
How do analysts rate ZVRA stock?
Of 9 analysts covering Zevra Therapeutics, 2 rate it Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ZVRA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.12, with estimates from $1.12 to $1.12 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.98, with estimates from $0.75 to $1.30 from 4 analysts.
What revenue do analysts expect from Zevra Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $152.83M, with estimates from $150.00M to $156.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $180.00M, with estimates from $157.10M to $201.96M.
How many analysts cover ZVRA?
9 analysts rate Zevra Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
ZVRA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors